Small amounts of artificial vanilla extract, also known as vanillin, are in a wide range of products, from baked goods to perfumes. But vanillin's versatility doesn't stop there. In a recent mouse study researchers report that this compound could also prevent or reduce psoriatic skin inflammation.
An international team of researchers has unraveled a crucial aspect of the molecular basis of autoimmune and inflammatory diseases such as psoriasis, rheumatoid arthritis and Crohn's disease. Focusing on the immunomodulatory cytokine IL-23 they discovered that its pro-inflammatory activity, which underlies a wide range of inflammatory diseases, critically depends on structural activation of the cytokine by its receptor, IL-23R.
People with psoriasis are at a higher risk to develop type 2 diabetes than those without psoriasis, and the risk increases dramatically based on the severity of the disease. Researchers found people with psoriasis that covers 10 percent of their body or more are 64 percent more likely to develop diabetes than those without psoriasis, independent of traditional risk factors such as body weight.
Researchers report the discovery of a key underlying immune mechanism that explains why to how our skin becomes inflamed from conditions such as atopic dermatitis, more commonly known as eczema. Toxin-producing bacteria on the surface of our skin induces a protein that causes our own cells to react and cause inflammation.
Stem cells in the skin remember an injury, helping them close recurring wounds faster, researchers have found. The discovery could advance research and treatment of psoriasis and other inflammatory diseases.
New research helps address a longstanding question about the inflammatory skin condition psoriasis: Why do skin lesions that have resolved with therapy recur in the same locations after a patient stops using topical steroids?
Solenopsins, the main toxic components of fire ant venom, chemically resemble ceramides, which are lipid-like molecules essential for maintaining for the barrier function of the skin. Solenopsin analogs can reduce skin thickening and inflammation in a mouse model of psoriasis, scientists have shown.
The more the surface area of the body is covered by psoriasis, the greater the risk of death for the patient suffering from the condition, according to a new analysis. Patients with psoriasis on 10 percent or more of their body are at almost double the risk of death.
Biological treatment of psoriasis shows a good efficacy in clinical trials. Since most analyses have focused on short-term outcomes of single biological agents, little has been known about long-term outcomes in clinical practice, where switching between biological agents is common. A study that followed 583 individuals for up to 10 years shows a satisfactory long-term effectiveness of biologic treatments.
A new study tested the efficacy of tildrakizumab, an antibody that targets only a very specific immune system pathway. More than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients who received placebos.
There were notably more remissions with Secukinumab and ixekizumab than under the comparator therapies for psoriasis. In future, the analysis of symptoms should not be limited to improvements at one time point.
A newly developed tissue scanner allows looking under the skin of psoriasis patients. This provides clinically relevant information, such as the structure of skin layers and blood vessels, without the need for contrast agents or radiation exposure.
Patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced a significant reduction in symptoms, including joint tenderness and swelling, have reported promising results when they were given a new drug.